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Abstract: Oral administration remains the most convenient way of delivering drugs. 
Recent advances in biotechnology have produced highly potent new molecules such as 
peptides, proteins and nucleic acids. Due to their sensitivity to chemical and enzymatic 
hydrolysis as well as a poor cellular uptake, their oral bioavailability remains very low. 
Despite sophisticated new delivery systems, the development of a satisfactory oral 
formulation remains a challenge. Among the possible strategies to improve the 
absorption of drugs, micro- and nanoparticles represent an exciting approach to enhance 
the uptake and transport of orally administered molecules. Increasing attention has been 
paid to their potential use as carriers for peptide drugs for oral administration. 
This article reviews the most common manufacturing methods for polymeric particles 
and the physiology of particle absorption from the gastrointestinal (GI) tract. In a second 
part, the use of polymeric particulate systems to improve the oral absorption of insulin is 
discussed. 
Keywords: Nanoparticle, microparticle, oral route, peptide, mechanisms of absorption, 
protein, insulin, calcitonin. 
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Introduction 
Advances in the field of biotechnology have brought a lot of new and potent active compounds. 
However, the development of these molecules as medicines is largely impaired by the fact that they are 
not administrable by the oral route. Indeed, the oral one is the most convenient route of administration 
for both patients and medical staff. However, administering peptide and protein drugs orally is a 
formidable challenge due to their very short life in the gastric and intestinal fluids [1]. In addition, they 
suffer from a poor absorption rate through the intestinal barrier. Among the different approaches 
developed, polymeric micro- and nanoparticles represent an interesting strategy. Indeed, they shield 
the encapsulated drug from the external harsh conditions; they also may favour the uptake by intestinal 
cells. 
Given orally, peptides and proteins are degraded by the enzymes from the gastric and intestinal 
juices rich in proteases such as trypsin or chymotrypsin. Therefore, they do not reach intact the site of 
absorption, namely the enterocytes. Furthermore, the brush border and the cytosol of the absorptive 
cells are full of peptidases that will degrade small peptides resulting from the hydrolysis of the proteins 
into amino acids that are readily resorbed in the blood. Thus, the first goal to develop an oral 
formulation for peptide and protein drugs is to reduce or even better to avoid enzyme degradation. 
Polymeric particles will isolate the encapsulated drug from the external medium therefore protecting 
the peptide from the peptidases, allowing, then, their uptake by enterocytes. After absorption, 
polymeric particles will slowly degrade according to a kinetic profile depending on the nature of the 
polymer, thus providing a sustained and controlled release of the drug [2]. 
Polymeric particles have been shown to cross the intestinal wall, although only in minute 
quantities. The size of the particles as well as the nature of the polymer are critical parameters involved 
in particle uptake by the GI tract. Therefore, this review will first introduce a brief overview of particle 
preparation methods and the physiology of particle absorption. Then, the studies using polymeric 
particles to improve oral insulin delivery will be reviewed.  
 
Polymeric Particulates: Definitions and Manufacturing 
 
Polymeric particles used for drug delivery are defined as colloidal systems made of solid polymers 
that may be classified according to their size and preparation processes (Figure 1). The term 
microparticle designates systems larger than 1 µm whereas nanoparticles are submicronic particles. 
Micro- and nanocapsules are composed of a polymeric wall containing a liquid inner core where the 
drug is entrapped while micro- and nanospheres are made of a solid polymeric matrix in which the 
drug can be dispersed. Active substances may be either adsorbed at the surface of the polymer or 
encapsulated within the particle. Particles may be produced by polymerization of synthetic monomers, 
or dispersion of synthetic polymers or natural macromolecules. The preparation methods have been 
extensively reviewed in the literature [3-6] and will only be briefly described here. 
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Figure 1: Different types of polymeric particles 
 
 
The physico-chemical properties of particles play a critical role in the rate of absorption by the 
intestinal tract. Since those properties are greatly influenced by the preparation method, it is useful to 
have a brief presentation of these techniques. As summarized in Table 1, the polymers used to make 
particles for oral administration are rather diverse. The choice of a preparation method depends greatly 
on both the nature of the drug and the polymer. 
 
Table 1: Nature of the polymers and preparation methods for polymeric particles 
intended for oral administration. 
Polymer Method 
Nature of the 
particles References 
PLA Emulsion-evaporation Spheres [62] 
 Emulsion-diffusion Spheres [63] 
 Salting out Spheres [63] 
 Dessolvation Capsules [64] 
 Interfacial precipitation Capsules [26] 
PLGA Emulsion-evaporation Spheres [62] 
 Interfacial precipitation Capsules  
[65] 
[66] 
PACA 
Interfacial 
polymerization 
Capsules 
[67] 
[24] 
 Emulsion polymerization Spheres 
[55] [68] 
[69] 
Nanosphere Nanosphere prepared by the double 
emulsion technique 
Nanocapsule
Entrapped drug Adsorbed drug 
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Table 1. Cont. 
Chitosan Emulsion-diffusion Spheres [70] 
Eudragit® Emulsion-diffusion Spheres [71] 
 Interfacial precipitation Capsules  [65] 
P(MMA-g-EG) 
Suspension 
polymerization 
Spheres [72] 
HPMC-AS Emulsion-evaporation Spheres [73] 
Poly FA:SA Phase inversion  Spheres [74] 
Insulin 
Dessolvation-
crosslinking 
Spheres [19] 
LHRH-n-butylcyanoacrylate Copolymerization Spheres [20] 
Cyclosporin A Emulsion-precipitation Spheres [22] 
Derivatized amino acids Self-aggregation Spheres [75, 76] 
Soybean protein hydrolysates Self-aggregation Spheres [77] 
Key to abbreviations : 
PLA : poly(lactic acid) 
PLGA : poly(lactic-co-glycolide) 
PACA : poly(alkylcyanoacrylate) 
Eudragit® : poly(methylacrylic acid-co-methylmethacrylate) 
P(MAA-g-EG) : poly(methacrylic-g-ethylene glycol) 
FA:SA : fumaric acid:sebacic acid 
HPMC-AS : hydroxypropylmethylcellulose acetate succinate 
LHRH : luteinizing hormone releasing hormone 
 
Particle formation by polymerization reactions (emulsion-polymerization) has been primarily 
developed for polymers such as poly(methylmethacrylate) (PMMA), poly(alkylcyanoacrylate) 
(PACA), and poly(methylidenemalonate) (PMM) [7-9]. Briefly, the water insoluble monomer is 
dispersed in an aqueous phase and the polymerization is induced and controlled by addition of a 
chemical initiator or by variations in physical parameters such as pH or γ-radiation in the presence or 
the absence of surfactants to stabilize the emulsion. Drugs are entrapped in the polymeric wall when 
added to the polymerization medium or adsorbed on preformed particles afterwards. 
The preparation of particles from preformed polymers is based on polymer precipitation (Figure 2). 
Basically, an organic solution of the polymer is emulsified in an aqueous solution with or without a 
surfactant. In a second step, the organic solvent is removed by different methods such as evaporation, 
diffusion or salting out under stirring to allow particle formation. With these techniques, the drug has 
to be at least partially soluble in an organic solvent to be encapsulated. This is a major limitation to the 
encapsulation of hydrophilic compounds such as peptides, proteins or nucleic acids. Therefore, 
alternative methods have been developed to increase the encapsulation rate of hydrophilic molecules. 
It is possible, for example, to derivatize a hydrophilic compound to form a hydrophobic complex [10, 
11]. A more common way is to use a double emulsion technique in which an aqueous solution of the 
Molecules 2005, 10 
 
69
hydrophilic compound is first emulsified in an organic solution of the polymer (Figure 2). The primary 
emulsion is then poured into a large volume of water with or without surfactant. Freeze fracture 
micrographs of these particles show the alveolar structure specific to this process [12, 13]. The double 
emulsion technique has a fairly good encapsulation efficiency for hydrophilic compounds, however, 
particle size is usually larger than with single emulsion technique [14]. 
Another way of preparing particles from a preformed polymer is the spray-drying method where 
the drug is solubilized or dispersed in an organic solution of the polymer to be nebulized in a hot air 
flow. The solvent is almost instantly evaporated and dried microparticles are readily recovered. This 
technique, easily applicable at the industrial scale, is used for hydrophilic [15, 16], as well as lipophilic 
[17, 18] molecules. However, particle size remains rather large, rarely smaller than 5 µm. Therefore, 
this method is seldom used in the context of oral administration. 
Some authors have used an interesting approach in which the drug itself was polymerized. 
Oppenheim et al. obtained 200 nm insulin nanospheres by dessolvation of the protein and crosslinking 
with glutaraldehyde [19]. Particle formation, however, was accompanied by a substantial degradation 
of the protein since an almost 80% loss in activity was observed. Hillery et al. developed a new 
technique of co-polymerization of a peptide (LHRH) and n-butylcyanoacrylate radicals followed by 
the precipitation of the co-polymer to form nanoparticles with an average diameter of 100 nm [20, 21].  
With this method, the peptide integrity and biological activity were preserved. More recently, Ford et 
al. reported the formation of approximately 300 and 800 nm nanoparticles made of the hydrophobic 
cyclosporin A [22].  
Nano- and microcapsule technology offers several advantages for improving the entrapment 
efficiency of lipophilic compounds, or for providing a controlled release system. It has also been used 
with hydrophilic drugs especially with oily suspensions of insulin [23, 24]. Micro- and nanocapsules 
may be prepared by interfacial polymerization from alkylcyanoacrylate monomers [25]. The drug and 
the monomer are then dissolved or dispersed in a mixture of ethanol and oil under magnetic stirring 
into an aqueous phase. Capsules may also be obtained from preformed polymer, based on a 
dessolvation process [26, 27]. Recently, a new method based on the emulsification-diffusion process 
has been described [28]. Vranckx et al. reported an interesting preparation method for capsules with a 
hydrophilic core that may be particularly attractive for peptides and proteins [29]. Lambert et al. also 
used this technique to encapsulate oligonucleotides where the nanocapsules were suspended in an 
aqueous medium more suitable for intravenous administration [30].  
Regardless of the preparation process, the ultimate physico-chemical properties of the particles are 
greatly influenced by the experimental conditions of manufacturing. For example, stirring mode and 
speed greatly influence the particle size and, similarly, the solvent elimination process will affect the 
hardening process and the final morphology of the particles. For more details, refer to the following 
reviews: Magenheim and Benita [31], Allémann et al. [3] and Alonso [4]. 
Once the particles are formed, spheres or capsules, a purification step is needed to remove the 
potentially toxic additives necessary for the manufacturing or to separate unincorporated drug. It is 
used as well as a concentration technique. This may be achieved by centrifugation or ultra-
centrifugation depending on the size of the particles, by filtration (centrifugal filtration or cross flow 
filtration), gel permeation or dialysis.  
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Figure 2:  Particle preparation methods by polymer precipitation, examples of single and 
double emulsion techniques 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final concentration and drying are usually achieved by lyophilisation. This step is crucial for 
preservation of formulation quality to ensure both drug and polymer stability. However, lyophilization 
may affect the particles themselves causing morphological changes or even wall rupture, especially in 
the case of capsules. Furthermore, particle aggregation may occur, generating resuspension problems. 
Optimizing the settings of the freeze-drying parameters and addition of lyoprotecting agents may 
correct this side effect [32, 33]. 
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From this brief overview, it is clear that various materials and numerous methods are available to 
prepare drug loaded polymeric particles. The choice is usually dictated by criteria such as 
biodegradability and biocompatibility, expected release profiles and compatibility with drugs.  
 
Absorption of Polymeric Particulates from the Gastrointestinal Tract 
 
Oral absorption of particulates has been described as early as 1844 (as cited in [34, 35]). Several 
studies conducted either after chronic or single administration defined the parameters and the 
mechanisms involved in intestinal absorption of particles. A better knowledge of the mechanisms 
implicated in particle absorption is needed to design new polymers and better-targeted systems for the 
oral route.  
Physiologically, gastrointestinal functions are to digest and to absorb nutrients, water and vitamins 
from food. On the other hand, it is also designed as a barrier to restrain the entry of pathogens, toxins 
and undigested macromolecules. The histological architecture of the enteric wall is schematically 
depicted in Figure 3.  
The GI tract is lined with an epithelium made of a mosaic of cells, among which absorptive cells 
(enterocytes) and goblet cells (secreting the mucus) may be distinguished. These cells are tightly held 
together and form a strong barrier covered by a layer of mucus. Lymphoid follicles, part of the gut 
associated lymphoid system (GALT), involved in the development of the mucosal immune response, 
are interspersed in the enterocyte layer. Lymphoid follicles may be diffusely distributed or clustered in 
so-called Peyer's patches. The number and location of Peyer's patches vary widely between species and 
individuals and are also age dependent [36]. These follicles are overlaid by the follicle-associated 
epithelium (FAE) which comprises enterocytes, M cells differentiated from the enterocytes, and a few 
goblet cells. It is the site where antigens are first encountered. FAE and the M cells have been 
described as a privileged place for particle uptake. 
Physicochemical properties of particles influence greatly their rate of uptake by the intestinal tract. 
The two main factors are the size and the nature of the polymer used to make the particles. Early 
studies on “persorbabiliy” of solid undissolved food particles showed that the uptake was determined 
by their size and hardness [37-39]. Those particles were later observed either in the blood or the 
lymph. Absorption of particles as big as 150 µm was reported and the influence of xenobiotics such as 
atropine, barbiturics or neostigmine was reported as well [35, 40]. 
Particles are described as crossing either at the level of Peyer’s patches or through the enterocyte 
layer. Peyer’s patches were for a long time thought as the only site of absorption for particles. This 
feature raised the rationale of using particulate formulations for the development of mucosal 
vaccination. The major interest of mucosal is that the resulting immunity will be expressed at the level 
of all the mucosae independently of where it has been induced [41, 42]. Therefore, numerous studies 
were published where a protein was encapsulated into nanoparticles for oral vaccination. 
Encapsulation of proteins not being under the scope of this paper, this aspect will not be developed; the 
readers are driven to the following review articles [43, 44]. It is clearly stated now that particle uptake 
may occur in Peyer’s patches, however, it is not the exclusive site of absorption and uptake at the level 
of non Peyer’s patch area is fully documented [45, 46]. 
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Figure 3:  Schematic representation of the intestinal epithelium with a view of a Peyer's 
patch and detail of the follicle associated epithelium.   
 
The uptake is preceded by the interaction between the particles and the cell surface. Therefore, the 
nature of the polymer; mainly, the hydrophobic/hydrophilic balance and the charge; used to make the 
particles as well as the possible presence of the drug at the particle surface will affect the rate of 
uptake. 
Once internalized, the particles are phagocytosed by macrophages and distributed in the whole 
body [43, 47, 48]. Particles are then preferentially encountered in the liver, the spleen and the lungs 
[49, 50].  
Despite some rules of thumb showing the influence of certain factors on particle absorption, there 
are still numerous discrepancies and the identification of the best carrier is still not defined. This is 
mainly due to the use of different in vivo models, with different administration regimen making 
difficult to compare the various reports [51]. 
Size and hydrophilicity of the particles have been clearly described as important factors 
influencing intestinal absorption [51]. However, there are still numerous discrepancies in the studies 
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reporting the internalization of particles with the same characteristics, therefore, the identification of 
the best carrier is still not defined. This is mainly due to the use of different in vivo models, with 
different administration regimen making difficult to compare the various reports [51]. 
Therefore, the use of an in vitro model would be greatly profitable to the development of new 
particulate drug carriers for the oral route. Such a model would allow the screening in a systematic 
manner of the effect of the physicochemical properties of the particles. Caco-2 cells derived from a 
colonic cancer cells has been tested for different types of particles and seems to be an interesting tool. 
[52-54]. However, all the parameters for this model have not been fully characterized.  
In summary, many studies have been conducted on particle absorption from the GI tract, and some 
discrepancies exist, especially regarding the uptake mechanisms, the location of the absorption site as 
well as the quantity of particle taken up, however, several conclusions can be drawn.  The absorption 
takes place primarily, but not exclusively, in the Peyer's patches at the level of the M cells. Uptake is 
very fast and seems to be the result of a transcellular mechanism but a paracellular pathway, although 
very unlikely, cannot be excluded. The particulate/cell membranes interface appears to play an 
important role and all the parameters involved in the binding of particles at the cell surface have not 
been yet identified. The modification of particle surface properties due to the nature of the polymer or 
due to the binding of specific proteins or lectins can modulate the absorption rate.  
 
Polymeric Particles for the Oral Administration of Peptides  
 
Combinatorial chemistry and the growing knowledge of the biochemistry of the body have lead to 
an ever-increasing number of therapeutic peptides and proteins for the treatment of diseases. However, 
these molecules often lack the stability that more traditional small molecular weight drug possesses. 
Encapsulation of the protein or peptide within polymeric carrier can physically protect the bioactive 
from proteolytic enzymes. Further, as stated before, these carriers have been shown to translocate 
across the intestinal mucosa and hence can facilitate the absorption of peptides and proteins from the 
gut lumen [51].  
The main body of literature about the use of particulates for oral drug delivery is devoted to 
insulin. In this review we will evaluate and discuss the major in vivo studies that have been conducted 
with polymeric particles (particularly using biodegradable poly(alkylcyanoacrylates) and polylactic 
polymers) loaded with insulin and administered by the oral route.  
The first attempt to seek hypoglycemic effects after oral administration of insulin-loaded 
nanoparticles to diabetic rats was reported by Couvreur et al. [55]. Insulin was adsorbed on the surface 
of 200 nm poly(alkylcyanoacrylate) nanoparticles. No decrease in glucose level was observed after 
oral administration to diabetic rats. Insulin, however, remained active after subcutaneous 
administration. This result suggests that the peptide was not protected from the proteolytic degradation 
in the gastrointestinal tract.  
Subsequently, 200 nm particles were directly prepared from cross-linked insulin [19]. 
Nanoparticles were administered to rats and mice intragastrically by gastric tube. The glucose blood 
level in some animals was reduced to about 15 to 20% of the initial level 3 hours after administration. 
However, the hypoglycemic effect was quite erratic and some animals responded poorly to the 
treatment whereas others developed hypoglycemic shocks. The authors speculated that these particles 
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were partially absorbed from the GI tract of mice and of normal and diabetic rats. The nanoparticles 
appeared to exert a slower but more pronounced response than a similarly administered commercially 
available Actrapid® formulation, although no dose response relationship was established. Moreover, 
the high doses of nanoparticles needed would preclude the development of a commercially viable 
product. 
Surprising results were obtained by Damgé et al. [23] with the encapsulation of insulin inside oil-
filled poly(isobutylcyanoacrylate) (PIBCA). In diabetic rats, nanocapsules given by a single 
intragastric dose, reduced glycemia by 50-60%. This effect appears 2 days after administration and 
was maintained for up 20 days depending on the insulin dose, although the amplitude of the 
pharmacological effect (minimum level of blood glucose) did not depend on the insulin dose. Free 
insulin did not affect glycemia when administered orally under the same experimental conditions [23]. 
Damgé et al., suggested that nanocapsules could protect the peptide from proteolytic degradation in the 
intestinal fluids as observed in the presence of different proteolytic enzymes in vitro [56]. Furthermore, 
the capacity of insulin nanocapsules to reduce glycemia can also be explained by their translocation 
through the intestinal barrier [56]. In recent studies the use of Texas Red®-labeled insulin allowed to 
visualize this translocation more readily [57]. Although this passage is certainly an important factor, it 
does not explain the duration of the hypoglycemia. The authors suggested that the prolonged action 
could be due to the retention of a proportion of the colloidal system in the gastrointestinal tract. In 
another study, a prolonged hypoglycemic effect was also observed with insulin entrapped in 
poly(alkylcyanoacrylate) nanospheres dispersed in an oily phase containing surfactant, suggesting that 
some components of the nanocapsules can act as absorption promoters [58]. Recently, insulin has also 
been encapsulated in water-containing nanocapsules. These nanocapsules, dispersed in a 
biocompatible microemulsion, could facilitate the intestinal absorption of the encapsulated insulin after 
oral administration, as suggested by the reduced glucose level observed in diabetic rats [59].  
Carino et al. encapsulated zinc insulin in various polyester (polylactic acid; PLA, poly(lactide-co-
glycolide); PLGA) and polyanhydride (poly-fumaric anhydride-co-sebacic anhydride; P(FA:SA) and 
fumaric acid and sebacic acid oligomers; FAO and SAO respectively) nanosphere formulations using 
phase inversion nanoencapsulation [60]. A specific formulation, 1.6% zinc insulin in PLGA with FAO 
and iron oxide additives was active orally when administered to normal fasted rats. This formulation 
was shown to have 11,4% of the efficacy of intraperitoneally delivered insulin and was able to control 
plasma glucose levels when faced with a simultaneously administered glucose challenge. The authors 
hypothesized that each components of the formulation contributes to the overall efficacy; the 
polyanhydride and iron oxide seems to be necessary, possibly to increase the bioadhesive properties of 
the spheres, allowing for greater interaction between the nanospheres and the gastrointestinal 
epithelium and possibly uptake of the nanospheres. 
Ma et al. developed PLA microcapsules loaded with insulin [61]. The particles were prepared by a 
water-in-oil-in-water emulsion/solvent extraction. 2.5 mg of insulin encapsulated in PLA 
microcapsules (2-5 µm) were administered orally to alloxan induced diabetic rats. The blood glucose 
lowering effect was quite erratic. Although in 68% of diabetic rats peripheral blood glucose level 
decreased by 68.5%, in 21% the blood glucose decreased by 39.7%, and in 12% of the diabetic rats no 
effect was found (the number of animals used in the study was sixty-six). The authors speculated that 
these differences might be the results of variability in absorption of insulin in the gastrointestinal tract. 
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Conclusions 
 
Although very scarce, particle absorption is still sufficient to enhance the oral bioavailability of 
some drugs such as insulin. Efforts need to be conducted, however, in developing new polymers and 
new surface characteristics to increase the particle affinity to the epithelium surface. On the other 
hand, one has to bear in mind that particle resorption is not a prerequisite. Indeed, the presence of a 
polymeric wall provides a protection from the gastrointestinal environment and may favor a prolonged 
contact with the epithelium that may be sufficient to increase the bioavailability of certain drugs.  
Although the oral route is one of the preferred modes for drug administration, owing to its non-
invasive nature, adequate peptide or protein drug delivery has not yet been attained via this route. This 
is, in part, a consequence of the low bioavailability presented by most oral protein delivery systems. 
This low bioavailability implies a large variation in absorption and high manufacturing costs, which 
are both unacceptable for the development of most peptide and protein drugs. As a result, millions of 
diabetics worldwide have to give themselves insulin shots daily, resulting in a high rate of side effects 
and non compliance in this treatment. The possibility of using biodegradable nano- or microparticles 
for oral administration of insulin has been a controversial issue. Even if a dosage form is developed to 
produce a reasonable bioavailability, reproducibility is another potential problem. For drugs such as 
insulin that have a relatively narrow therapeutic window, the effects of age, genomics factors, 
pathophysiological conditions and other individual variations on GI absorption must be carefully 
investigated. Finally, insulin requires chronic administration and hence the effects of long-term oral 
administration of absorption carriers on both the GI and systemic physiology must also be seriously 
evaluated. 
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